Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$65.55

-4.48 (-6.40%)

08:03
10/13/16
10/13
08:03
10/13/16
08:03

bluebird bio says achieved general agreement on regulatory path for TDT

bluebird bio announced it will outline today key activities underway intended to advance the company's LentiGlobin programs in transfusion-dependent beta-thalassemia, or TDT, and severe sickle cell disease, or SCD. The presentation will focus on three key aspects of these activities: 1) potential improvements in transduction efficiency and manufacturing; 2) updates to the protocol for the company's ongoing HGB-206 clinical trial in SCD; and 3) regulatory plans for the company's LentiGlobin drug product candidate in TDT. bluebird bio is working closely with regulatory agencies in the United States and Europe to bring LentiGlobin to patients with TDT who can benefit, as quickly as possible, and has reached general agreement with the U.S. FDA and the European Medicines Agency, respectively, on the regulatory paths forward, the company said. "At bluebird bio we have an incredibly ambitious goal: to deliver one-time, transformative therapies to patients with rare genetic diseases and cancer. We are relentless in our efforts to continue innovating in pursuit of that goal, and we have made substantial advances in the transduction and manufacturing processes, translational research, and clinical development. By incorporating manufacturing Process 2 into our LentiGlobin clinical trials, we believe we can achieve our ultimate goal of increasing hemoglobin production in patients treated with LentiGlobin drug product. In sickle cell disease we have used our early clinical data to identify and implement multiple distinct improvements with the potential to overcome the unique challenges presented by this complex disease. We are hopeful that the tremendous work done by our research and development teams will yield improved outcomes for patients in the clinic in 2017 and beyond, and that the regulatory progress we are making will enable us to bring these treatments to patients as quickly as possible. We anticipate seeing many catalysts across our programs in the next 15 months, including initial clinical data from our Phase 1 clinical study of our bb2121 product candidate in relapsed/refractory multiple myeloma and updates on our Lenti-D program in cerebral adrenoleukodystrophy," said bluebird CEO Nick Leschly.

  • 13

    Oct

  • 06

    Nov

  • 29

    Nov

BLUE bluebird bio
$65.55

-4.48 (-6.40%)

09/15/16
09/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Hold from Sell at Canaccord with analyst Alex Brooks citing valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from Perform at Oppenheimer analyst Brian Nagel citing the potential for better near-term sales trends as "weaker players" in sporting goods retail fail. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying volume trends across the company's commercial portfolio suggests the base business is "on sustainable footing." 4. Petrobras (PBR) upgraded to Neutral from Underperform at Macquarie with analyst Giacomo Romeo saying near-term liquidity is less concerning after recent divestitures, an improved political outlook, and the re-gained access to the bond market. 5. bluebird bio (BLUE) upgraded to Conviction Buy from Buy at Goldman with analyst Salveen Richter saying he expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/16
ROTH
09/22/16
INITIATION
Target $87
ROTH
Buy
bluebird bio reinstated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach assumed coverage of bluebird bio with a Buy rating and $87 price target based on a sum-of-parts, probability-adjusted NPV analysis of the company's pipeline. The analyst believes bluebird bio can no longer be considered a fledgling given the clinical success seen in its Lenti-D and Lentiglobin programs, both hatched from the company's versatile core lentiviral technology platform.
09/22/16
09/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Packaging Corp. (PKG) initiated with a Sell at Goldman. 2. Netlist (NLST) initiated with a Buy at B. Riley. 3. Weyerhaeuser (WY) initiated with a Conviction Buy at Goldman. 4. bluebird bio (BLUE) reinstated with a Buy at Roth Capital. 5. Dentsply Sirona (XRAY) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

16:37
04/27/17
04/27
16:37
04/27/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 4/17 Money Supply…

16:36
04/27/17
04/27
16:36
04/27/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 4/26 Fed Balance…

RMD

ResMed

$72.85

1.1 (1.53%)

16:36
04/27/17
04/27
16:36
04/27/17
16:36
Earnings
ResMed reports Q3 non-GAAP EPS 71c, consensus 71c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

HEP

Holly Energy

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Hot Stocks
Holly Energy raises quarterly distribution 7.8% to 62c per unit »

The board of directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BIDU

Baidu

$187.86

1.19 (0.64%)

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Hot Stocks
Baidu reports 451,000 active online marketing customers in Q1 »

Representing a 23.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MOBL

MobileIron

$4.45

-0.05 (-1.11%)

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Earnings
Breaking Earnings news story on MobileIron »

MobileIron backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    Jun

LPLA

LPL Financial

$38.52

-0.84 (-2.13%)

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Hot Stocks
Breaking Hot Stocks news story on LPL Financial »

LPL Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

MSFT

Microsoft

$68.27

0.44 (0.65%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Hot Stocks
Nadella says Q1 results reflect 'trust' in Microsoft Cloud »

"Our results this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 09

    May

MOBL

MobileIron

$4.45

-0.05 (-1.11%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Earnings
MobileIron sees Q2 revenue $42.5M-$44.5M, consensus $43.83M »

Non-GAAP gross margin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    Jun

BIDU

Baidu

$187.86

1.19 (0.64%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Hot Stocks
Baidu CFO Jennifer Li to step down »

Baidu also announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

URBN

Urban Outfitters

$23.15

-0.55 (-2.32%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Hot Stocks
Urban Outfitters announces changes to store leadership »

Urban Outfitters, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INT

World Fuel Services

$36.79

-0.31 (-0.84%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Earnings
World Fuel Services reports Q1 adjusted EPS 64c, consensus 49c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

IPAR

Inter Parfums

$36.95

0.2 (0.54%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Hot Stocks
Inter Parfums says doesn't expect Q1-type growth in remaining quarter »

""First quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOBL

MobileIron

$4.45

-0.05 (-1.11%)

16:34
04/27/17
04/27
16:34
04/27/17
16:34
Earnings
MobileIron reports Q1 non-GAAP EPS (6c), consensus (8c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    Jun

IPAR

Inter Parfums

$36.95

0.2 (0.54%)

16:33
04/27/17
04/27
16:33
04/27/17
16:33
Earnings
Inter Parfums backs FY17 EPS $1.20-$1.24, consensus $1.25 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MERC

Mercer

$12.55

0.1 (0.80%)

16:33
04/27/17
04/27
16:33
04/27/17
16:33
Earnings
Mercer reports Q1 EPS 15c, consensus 28c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SGMS

Scientific Games

$22.80

-0.1 (-0.44%)

16:33
04/27/17
04/27
16:33
04/27/17
16:33
Earnings
Scientific Games reports Q1 EPS ($1.14), consensus (72c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 30

    May

VDSI

VASCO Data Security

$13.60

-0.05 (-0.37%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
Breaking Earnings news story on VASCO Data Security »

VASCO Data Security sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

IPAR

Inter Parfums

$36.95

0.2 (0.54%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
Inter Parfums reports Q1 revenue $143.1M, consensus $120.19M. »

"The 57% increase in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VDSI

VASCO Data Security

$13.60

-0.05 (-0.37%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
VASCO Data Security reports Q1 non-GAAP EPS 8c, consensus (3c) »

Reports Q1 revenue $42M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

LRN

K12

$20.26

-0.17 (-0.83%)

16:32
04/27/17
04/27
16:32
04/27/17
16:32
Earnings
K12 sees Q4 revenue $215M-$220M, consensus $223.96M »

Sees Q4 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

EHTH

eHealth

$11.74

0.23 (2.00%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
Breaking Earnings news story on eHealth »

eHealth sees FY17 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

  • 30

    May

  • 06

    Jun

BIDU

Baidu

$187.86

1.19 (0.64%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
Baidu sees Q2 revenue $2.974B-$3.048B, consensus $3.03B »

Representing an annual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

LRN

K12

$20.26

-0.17 (-0.83%)

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Earnings
K12 reports Q3 EPS 23c, consensus 25c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

16:31
04/27/17
04/27
16:31
04/27/17
16:31
Options
Preliminary option volume of 15.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.